{"schema_version":"secwatch.filing_event.v1","accession":"0001390478-23-000025","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.834890+00:00","generated_at":"2026-06-08T06:20:01.016286+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"SELLAS Q3 net loss $9.3M; GPS Phase 3 enrollment complete, SLS009 shows CR in AML","bullets":["Net loss $9.3M ($0.33/share) vs $7.0M in Q3 2022; cash $4.0M as of Sep 30, 2023; subsequent $4.0M offering.","Phase 3 REGAL trial of GPS in AML expected to complete enrollment (ex-China) in November 2023; interim data late 2023/early 2024.","SLS009 Phase 2a in AML: first patient achieved complete response, six of seven patients alive; anti-leukemic effects in all.","FDA granted Orphan Drug Designation for SLS009 in AML and Fast Track for r/r PTCL.","Anticipating $13.0M milestone from 3D Medicines upon China enrollment in REGAL in Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001390478-23-000025","json":"https://secwatch.observer/filing/0001390478-23-000025.json","markdown":"https://secwatch.observer/filing/0001390478-23-000025.md","text":"https://secwatch.observer/filing/0001390478-23-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000139047823000025/0001390478-23-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000139047823000025/sls-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:20:01.016286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8afe44927c30bbed9f2e5ccae19ae0fd7103ada9","claim":"SELLAS Life Sciences Group, Inc. reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2023 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1390478/000139047823000025/0001390478-23-000025-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}